Warberg Asset Management’s Regentis Biomaterials RGNT Stock Holding History

Warberg Asset Management’s Portfolio RGNT Stock Details RGNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$306K	Buy	+86,980	New	+$248K	0.06%	99
2026 Q1	–	Sell	-19,093	Closed	-$127K	–	235
2025 Q4	$127K	Buy	+19,093	New	+$131K	0.02%	134

Other funds holding RGNT

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Warberg Asset Management's RGNT Position: Q2 2026 in Review

Warberg Asset Management opened a new position in Regentis Biomaterials (RGNT) in Q2 2026: 86,980 shares worth $306K. The stake represents 0.06% of the portfolio and ranks #99 among its holdings. This is a return to the name: Warberg Asset Management previously reported a position in RGNT as recently as Q4 2025.

Warberg Asset Management first reported a position in RGNT in Q4 2025 and has held it in 2 quarters since. 6 funds tracked by Wall St. Rank hold RGNT as of Q2 2026.

Warberg Asset Management held 86,980 shares of Regentis Biomaterials worth $306K as of Q2 2026.
Regentis Biomaterials was a new Warberg Asset Management position in Q2 2026.
Regentis Biomaterials made up 0.06% of Warberg Asset Management's portfolio in Q2 2026, its #99 holding.
Warberg Asset Management first reported a position in Regentis Biomaterials in Q4 2025 and has held it in 2 quarters since.
6 funds tracked by Wall St. Rank held Regentis Biomaterials as of Q2 2026.

Based on Warberg Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.